| dc.contributor.author | Ahmad, Tariq | |
| dc.date.accessioned | 2021-05-18T07:49:14Z | |
| dc.date.available | 2021-05-18T07:49:14Z | |
| dc.date.issued | 2021-01 | |
| dc.identifier.citation | Sazonovs A, Ahmad T, Anderson CA. Underpowered PANTS: A Response to the Conclusions of "Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab". Gastroenterology. 2021 Jan;160(1):470-471. doi: 10.1053/j.gastro.2020.05.102. Epub 2020 Oct 3. | en_US |
| dc.identifier.pmid | 33022279 | |
| dc.identifier.doi | 10.1053/j.gastro.2020.05.102 | |
| dc.identifier.uri | https://rde.dspace-express.com/handle/11287/621716 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier Science | en_US |
| dc.relation.url | https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(20)35225-2 | en_US |
| dc.rights | © 2021 by the AGA Institute | en_US |
| dc.subject | Response | en_US |
| dc.subject | HLA Class II Haplotypes | en_US |
| dc.subject | Development of Immunogenicity | en_US |
| dc.subject | Adalimumab | en_US |
| dc.subject | Infliximab | en_US |
| dc.subject | Wessex Classification Subject Headings::Gastroenterology | en_US |
| dc.title | Underpowered PANTS: A Response to the Conclusions of "Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab" | en_US |
| dc.type | Letter | en_US |
| dc.identifier.journal | Gastroenterology | en_US |
| dc.description.funding | Tariq Ahmad has received unrestricted research grants, advisory board fees, speaker honorariums, and
support to attend international meetings from AbbVie, Merck, Pfizer, NAPP, Celltrion, and Hospira. The remaining authors disclose no conflicts. | en_US |
| dc.type.version | Published | en_US |
| dc.description.admin-note | published version, accepted version, submitted version | en_US |
